Abstract
Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8+ T cells, while direct presentation of antigen dominates activation of tumor-specific CD4+ T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.
Original language | English (US) |
---|---|
Pages (from-to) | 70-74 |
Number of pages | 5 |
Journal | Cancer Immunology Immunotherapy |
Volume | 46 |
Issue number | 2 |
DOIs | |
State | Published - 1998 |
Keywords
- Cell-based cancer vaccines
- Cross- priming
- Immuno herapy
- MHC class II
- Tumor antigen presentation
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research